Qiagen's Parse Biosciences Hit with $4.8M Jury Award in Patent Dispute

Regulation
โดย Seeking Alpha·US·Read original
Summary · why it matters

A Delaware federal jury has ordered Qiagen subsidiary Parse Biosciences to pay more than $4.8 million in damages for infringing three patents licensed by 10x Genomics' Scale Biosciences unit from Roche. The jury also rejected Parse's claims that the patents were invalid, affirming they are valid and enforceable. The damages are based on a 14% royalty rate on sales of infringing products from February 2021 through June 30, 2026. 10x Genomics said it will seek a permanent injunction and additional awards for attorneys' fees and enhanced damages in post-trial proceedings.

Impact on stocks 3

Biotech & Genomic Medicine± Mixed · 2 stocks
Qiagen NV
QGEN
▼ NegativeRegulationrelevance

Qiagen subsidiary Parse Biosciences ordered to pay $4.8M for infringing patents, with injunction and enhanced damages sought.

10X Genomics Inc
TXG
▲ PositiveRegulationrelevance

Jury affirmed validity of patents licensed by 10x Genomics' Scale Biosciences unit and awarded damages, strengthening its IP position.

Health Care▲ · 1 stocks
Roche Holding AG
ROP
▲ PositiveRegulationrelevance

Roche-licensed patents were upheld as valid and infringed, benefiting its patent licensing position.

Off-coverage companies 2

Parse BiosciencesPrivate▼ Negative
Regulationrelevance

Parse Biosciences hit with $4.8M jury award for patent infringement and faces possible injunction.

Scale BiosciencesPrivate▲ Positive
Regulationrelevance

Scale Biosciences' licensed patents were affirmed valid and infringed, supporting its patent enforcement.

© 2026 MarketDXNews